Aligos Therapeutics, Inc. (ALGS)
Nasdaq · Healthcare · Biotechnology
$5.40−2.53%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $33.7M
- 52-week range
- $3.98 – $13.69
- 52-week change
- −43.70%
- EPS (trailing)
- −$7.41
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $2.2M (−39.46%)
- Net income
- −$24.2M
- Operating margin
- −4024.9%
- Diluted EPS
- −$2.45
From the company’s annual report on SEC EDGAR.
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Headquarters: South San Francisco, United States · 82 employees · aligos.com